| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 08/26/2008 | US7417130 DNA library comprising nucleotide sequences coding polypeptide containing leucine repeats for monitoring binding and regulation of ligand and cofactor interactions |
| 08/26/2008 | US7417129 Combinatorial libraries of monosaccharides |
| 08/26/2008 | US7417038 administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity; a beta receptor blocker or a compound which inhibits the effect of aldosterone |
| 08/26/2008 | US7417036 adding organic solvent and dissolivng adefovir dipivoxil ultrasonically to form solution, and spray drying; have different melting points, solubility, and density |
| 08/26/2008 | US7417034 Pharmaceutically active uridine esters |
| 08/26/2008 | US7417029 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 08/26/2008 | US7416868 polypeptide comprising an amino acid sequence having polyene polyketide synthase activity; involved in the biosynthesis of novel polyketides, inhibitors of fungal cell growth and cancer cell growth |
| 08/26/2008 | US7416858 Forming a convalent conjugate of a peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety |
| 08/26/2008 | US7416848 DNA encoding SNORF25 receptor |
| 08/26/2008 | US7416846 A vaccine composition comprising virus-like particles (VLPs) containing L1 proteins or functional L1 protein derivatives from human papillomavirus (HPV) 16, HPV 18, HPV 31 and HPV 45 genotypes and an adjuvant;anticarcinogenic agents; antumor agents; viricides |
| 08/26/2008 | US7416745 Preventives or remedies for infection, anti-endotoxin agents, vaccine adjuvants and growth promoters |
| 08/26/2008 | US7416734 Vaccines for Mycoplasma bovis and methods of use |
| 08/26/2008 | US7416733 inhibiting Flavivirus infection by inhibiting the fusion between the virion envelope and a cell membrane; E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins |
| 08/26/2008 | US7416732 truncated papillomavirus L1 protein consisting of an amino acid sequence having one or more carboxy terminal amino acid residues deleted from a full length L1 amino acid sequence, and amino acid residues from a second protein replacing deleted amino acid residues in the truncated L1 protein. |
| 08/26/2008 | US7416726 Cytotoxicity; therapeutic antibody |
| 08/26/2008 | CA2432129C Pyrazole compounds useful as protein kinase inhibitors |
| 08/26/2008 | CA2403441C Antimicrobial bioabsorbable materials |
| 08/26/2008 | CA2378487C Antibiotic(s)-polymer combination |
| 08/26/2008 | CA2361614C Compositions for treating inflammatory response |
| 08/26/2008 | CA2304977C Equine feed product containing lactobacillus |
| 08/26/2008 | CA2274825C Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase |
| 08/26/2008 | CA2171550C Nucleosides with anti-hepatitis b virus activity |
| 08/26/2008 | CA2160779C Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient |
| 08/21/2008 | WO2008101084A2 Methods and compositions for the disruption of biofilms |
| 08/21/2008 | WO2008100547A2 Compositions comprising lamiridosin, iridoids or derivatives thereof for treatment of hepatitis c or hepatitis b |
| 08/21/2008 | WO2008100453A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
| 08/21/2008 | WO2008099928A1 Placental protein having action of regulating protease activity and its related gene |
| 08/21/2008 | WO2008099913A1 Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient |
| 08/21/2008 | WO2008099911A1 Broad-spectrum antiviral composition having excellent storage stability |
| 08/21/2008 | WO2008099874A1 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
| 08/21/2008 | WO2008099492A1 Pyrimidine nucleoside derivative and salt thereof |
| 08/21/2008 | WO2008099368A1 Macrolide derivatives as antibacterial agents |
| 08/21/2008 | WO2008099175A1 Camp dependent induction of autophagy |
| 08/21/2008 | WO2008099022A1 10-sulfonyl-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| 08/21/2008 | WO2008099021A1 Dibenzodiazepinones useful as hepatitis c virus inhibitors |
| 08/21/2008 | WO2008099020A1 1,1-dioxo-1-thia-5,10-diazadibenzocycloheptenes useful as hepatitis c virus inhibitors |
| 08/21/2008 | WO2008098985A2 Pharmaceutical composition for the treatment of il-8 mediated diseases |
| 08/21/2008 | WO2008098955A2 Antibacterial combination of a tricyclic carbapenem and an antibiotic |
| 08/21/2008 | WO2008098859A1 Hcv polymerase inhibitors |
| 08/21/2008 | WO2008098484A1 Recombinant l1 proteins of human papilloma virus and uses thereof |
| 08/21/2008 | WO2008098471A1 A crystalline form of entecavir, its preparation, pharmaceutical compositions thereof and uses |
| 08/21/2008 | WO2008098374A1 Salts, prodrugs and polymorphs of fab i inhibitors |
| 08/21/2008 | WO2008098368A1 Inhibitors of hepatitis c ns3 protease |
| 08/21/2008 | WO2008078305A3 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| 08/21/2008 | WO2008078305A2 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| 08/21/2008 | WO2008070347A3 Betulin-peptide conjugates |
| 08/21/2008 | WO2008068048A3 A novel passive vaccine for candida infections |
| 08/21/2008 | WO2007139955A3 Triazole compounds that modulate hsp90 activity |
| 08/21/2008 | WO2007072022A3 Composition comprising an antigen-recognizing molecule and a lipid-based carrier |
| 08/21/2008 | US20080200558 Inhibitory or blocking agents of molecular generating and/or/ inducing functions |
| 08/21/2008 | US20080200557 N-substituted dopamine derivatives; septic shock, microbial infection, carcinogenesis, a mutation, Parkinson's or Alzheimer's disease, toxic effects of chemotherapy or radiation therapy; N-acetyldopamine; 3-methoxy dopamine |
| 08/21/2008 | US20080200539 Using mixture of triacetin, tolnaftate, and synthetic vitamin A; therapy for skin and nail infections; reducing moisture of affected tissue |
| 08/21/2008 | US20080200530 compound is a selective 5-HT2A inverse agonist or inhibits JC virus infection of human glial cells in patients with carcinomas, lymphoproliferative disorder, HIV, AIDS, immunosupressive therapy; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-fluoro-phenyl)-urea; pyrazole, urea or thiourea |
| 08/21/2008 | US20080200513 Pyridine N-Oxides As Antiviral Agents |
| 08/21/2008 | US20080200512 Hepatitis C virus polymerase inhibitors |
| 08/21/2008 | US20080200511 Novel Compounds and Methods of Using the Same |
| 08/21/2008 | US20080200509 Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth |
| 08/21/2008 | US20080200497 inhibitors of the hepatitis C virus NS3 protease; azalactone intermediate reacted with cycloalkylsulfonamide and decylization; urea or carbamate-terminated alkylglycine. hydroxyproline, cyclopropylglycine tripeptide |
| 08/21/2008 | US20080200465 Antipathogenic benzamide compounds |
| 08/21/2008 | US20080200445 Heterocyclic aspartyl protease inhibitors |
| 08/21/2008 | US20080200435 Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors |
| 08/21/2008 | US20080200423 Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents |
| 08/21/2008 | US20080200420 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 08/21/2008 | US20080200407 Suppress the immunoreactivity of a CpG motif and preventing and treating immune-mediated diseases such as arthritis |
| 08/21/2008 | US20080200398 Compounds For Enzyme Inhibition |
| 08/21/2008 | US20080199917 Using vector comprising early gene modifications as genetic transfer element in gene therapy; gnentic vaccines |
| 08/21/2008 | US20080199864 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 08/21/2008 | US20080199509 Preventing, reducting biofilms by administering charged polyamino acid; antiinflammatory agents; respiratory system disorders |
| 08/21/2008 | US20080199494 Vaccine |
| 08/21/2008 | US20080199493 cytomegalio viruses; herpes virus; maintenance high level of immunology response; therapy or prevention of infections; genetic engineered vector; gene expression of antigen or fusion protein |
| 08/21/2008 | US20080199491 vaccine containing antigen and non-liquid adjuvants ; implantable pellet, capsule, tablet, powder or aerosol |
| 08/21/2008 | US20080199487 Such as (2S,3S,4R)-1-O-( alpha -D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol; kits |
| 08/21/2008 | US20080199486 Grp94-based compositions and methods of use thereof |
| 08/21/2008 | US20080199483 Long lasting fusion peptide inhibitors of viral infection |
| 08/21/2008 | US20080199474 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 08/21/2008 | US20080199458 Therapeutic mixture comprising St. john's wort and preferential immunoglobulins for use in treatment of viral infections |
| 08/21/2008 | US20080199456 Immunogens; vaccines; fusion proteins; antibodies; host cells; diagnostic kits |
| 08/21/2008 | US20080199451 Composition for the Treatment and/or Prevention of Attacks by Biological Agents |
| 08/21/2008 | US20080199446 Uronic Acid and Probiotics |
| 08/21/2008 | US20080199445 Compositions and methods for treatment of microbial infections |
| 08/21/2008 | US20080199435 IL-8 Like Protein |
| 08/21/2008 | US20080199405 Polypeptide comprising a soluble Mycobacterium tuberculosis antigen; vaccines |
| 08/21/2008 | DE102007007698A1 Verwendung einer hochemulgierten Silikonöl-Emulsion (HSE)zur Herstellung eines Medikamentes Use of a highly emulsified silicone oil emulsion (HSE) for preparing a medicament |
| 08/21/2008 | DE102007007629A1 Verfahren zur Herstellung von 5-Hydroxymethyl-furfural über 5-Acyloxymethyl-furfural als Zwischenprodukt Process for the preparation of 5-hydroxymethylfurfural on 5-acyloxymethylfurfural as an intermediate |
| 08/21/2008 | DE102007007318A1 Coating composition for bioactive textile materials, useful e.g. for producing wound dressings, comprises layer-forming inorganic nanoparticulate sol and active component, e.g. natural oil |
| 08/21/2008 | CA2713977A1 Methods and compositions for the disruption of biofilms |
| 08/21/2008 | CA2679849A1 Functionally selective alpha2c adrenoreceptor agonists |
| 08/21/2008 | CA2678151A1 Broad-spectrum antiviral composition with excellent preservation stability |
| 08/21/2008 | CA2678036A1 Functionally selective alpha2c adrenoreceptor agonists |
| 08/21/2008 | CA2677905A1 Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections |
| 08/21/2008 | CA2677783A1 Compositions and methods for treatment of liver disease |
| 08/21/2008 | CA2677747A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
| 08/21/2008 | CA2676297A1 Inhibitors of hepatitis c ns3 protease |
| 08/21/2008 | CA2675257A1 Hiv combination vaccine and prime boost method |
| 08/20/2008 | EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use |
| 08/20/2008 | EP1958960A2 A process for the preparation of a non-toxic anthrax vaccine |
| 08/20/2008 | EP1958958A1 Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
| 08/20/2008 | EP1958956A2 Peptidomimetic protease inhibitors |
| 08/20/2008 | EP1958666A1 Heterocyclic-substituted alkanamides as therapeutic compounds |
| 08/20/2008 | EP1958637A1 Pharmaceutical composition for the treatment of IL-8 mediated diseases |